Episode 19: A Between the Biotech Waves Conversation with JeanFrancois Formela, Partner at Atlas Venture & multi-biotech company founder
Between the Biotech Waves
00:00
Is There a Continuous Evolution in the Genome Editing Sector?
Bluebird by Bluebird Bios is a transfusion dependent of the Lecemia drug, right? Yeah, sure. You know, and you're right, I think, but we unite to recall, right, the whole controversy around HCV and Gilead's drug that you had this influx. It clearly a lot of backlash, which I don't think was justified. No, absolutely. Jeff, as always, wonderful to talk to you. Look forward to continuing to build more companies with you. Well, same here. Thank you for listening to the BioTech conference.
Transcript
Play full episode
